Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227375 | 1.00 | CCR5 (0.67) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL5578956 | 0.99 | CCR5 (0.67) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL5578959 | 0.99 | CCR5 (0.67) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL6187241 | 0.93 | CCR5 (0.59) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL5578823 | 0.92 | CCR5 (0.58) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL5578824 | 0.92 | CCR5 (0.58) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL6185398 | 0.91 | CCR5 (0.68) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL6186447 | 0.91 | CCR5 (0.74) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL6186404 | 0.89 | CCR5 (0.77) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL6186791 | 0.88 | CCR5 (0.61) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267114-A1 | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-01 | — | — | US | claimed |
| EP-1541574-A1 | TRIAZASPIRO 5.5 UNDECANE DERIVATIVES AND DRUGS COMPRISI NG THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20050267114-A1 | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-01 | — | — | US | disclosed |
| EP-1541574-A1 | TRIAZASPIRO 5.5 UNDECANE DERIVATIVES AND DRUGS COMPRISI NG THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267114-A1 | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | HLA-DRB1, TLR5, HLA-C | CCR5 350/4885CXCR4 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.